SCHEMBL5543262

SCHEMBL5543262

[CH2]c1cccc2c1-c1ccccc1C2

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOA P21397 2/20 0.46
POLB P06746 1/20 0.42
HTR2B P41595 1/20 0.42
MAPT P10636 3/20 0.39
ALDH1A1 P00352 2/20 0.39
KDM4E B2RXH2 2/20 0.39
NPC1 O15118 2/20 0.39
RAB9A P51151 2/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
LMNA P02545 1/20 0.39
HPGD P15428 1/20 0.39
BCHE P06276 1/20 0.39
CES1 P23141 1/20 0.39
DRD2 P14416 1/20 0.38
DRD4 P21917 1/20 0.38
DRD3 P35462 1/20 0.38
MAPK8 P45983 2/20 0.37
MAPK9 P45984 2/20 0.37
PLK4 O00444 1/20 0.37
DAPK3 O43293 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30403300 0.79 MAOA (0.56) MAOAPOLBHTR2BMAPTALDH1A1
SCHEMBL1626146 0.74 MAOA (0.52) MAOAPOLBHTR2BMAPTALDH1A1
SCHEMBL18455523 0.74 MAOA (0.46) MAOAPOLBHTR2BMAPTALDH1A1
SCHEMBL11814243 0.74 MAOA (0.46) MAOAPOLBHTR2BMAPTALDH1A1
SCHEMBL1626149 0.74 MAPT (0.61) MAOAPOLBHTR2BMAPTALDH1A1
SCHEMBL2048985 0.74 ALDH1A1 (0.48) MAOAPOLBHTR2BMAPTALDH1A1
SCHEMBL9810975 0.74 MAOA (0.46) MAOAPOLBHTR2BMAPTALDH1A1
SCHEMBL789190 0.74 MAOA (0.46) MAOAPOLBHTR2BMAPTALDH1A1
SCHEMBL21694436 0.74 TDP2 (0.47) MAOAPOLBHTR2BMAPTALDH1A1
SCHEMBL313560 0.74 MAOA (0.46) MAOAPOLBHTR2BMAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023088772-A1 RENEWABLE JET PRODUCTION FROM CATALYTIC PYROLYSIS FEEDSTOCK IFP Energies Nouvelles (FR) 2023-05-25 WO disclosed
WO-2023088771-A1 RENEWABLE DIESEL PRODUCTION FROM CATALYTIC PYROLYSIS FEEDSTOCK IFP Energies Nouvelles (FR) 2023-05-25 WO disclosed
CN-102532162-B 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMA CO LTD 2015-05-27 CN disclosed
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
CN-101255170-A 2,3-dihydroimidazo[2,1-b]oxazole compound OTSUKA PHARMA CO LTD (JP) 2008-09-03 CN disclosed
CN-101172981-A 2,3-dihydroimidazo[2,1-b]oxazole compound OTSUKA PHARMA CO LTD (JP) 2008-05-07 CN disclosed
CN-100366624-C 2, 3-dihydro-6-nitroimidazo [2,1-b ] * azole compounds OTSUKA PHARMA CO LTD (JP) 2008-02-06 CN disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
CN-1705670-A 2, 3-dihydro-6-nitroimidazo [2, 1-b ] oxazole compounds OTSUKA PHARMA CO LTD (JP) 2005-12-07 CN disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 MAOA 2885/4885POLB 1637/4885HTR2B 3791/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.